Roche (OTCMKTS:RHHBY) Upgraded to Hold at Deutsche Bank Aktiengesellschaft

Roche (OTCMKTS:RHHBY) was upgraded by analysts at Deutsche Bank Aktiengesellschaft from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Marketbeat.com reports.

Separately, Argus reiterated a “hold” rating on shares of Roche in a research report on Monday, March 4th. One investment analyst has rated the stock with a sell rating, five have given a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Roche currently has an average rating of “Hold” and an average target price of $40.00.

Roche Trading Up 0.5 %

Shares of OTCMKTS RHHBY opened at $32.81 on Friday. The company has a quick ratio of 1.04, a current ratio of 1.35 and a debt-to-equity ratio of 0.75. The firm’s 50-day moving average is $31.21 and its 200-day moving average is $33.29. Roche has a 1 year low of $29.20 and a 1 year high of $40.48.

Hedge Funds Weigh In On Roche

A number of hedge funds and other institutional investors have recently made changes to their positions in RHHBY. Hancock Whitney Corp raised its stake in Roche by 2.4% during the 1st quarter. Hancock Whitney Corp now owns 28,995 shares of the company’s stock worth $926,000 after buying an additional 678 shares during the period. SVB Wealth LLC raised its position in shares of Roche by 2.6% during the first quarter. SVB Wealth LLC now owns 16,646 shares of the company’s stock worth $531,000 after purchasing an additional 426 shares during the period. Motco grew its position in shares of Roche by 42.4% in the 1st quarter. Motco now owns 18,932 shares of the company’s stock valued at $604,000 after purchasing an additional 5,637 shares during the period. ORG Partners LLC bought a new stake in Roche during the 1st quarter worth approximately $689,000. Finally, Bard Financial Services Inc. raised its holdings in Roche by 2.0% during the 1st quarter. Bard Financial Services Inc. now owns 20,200 shares of the company’s stock worth $645,000 after buying an additional 400 shares during the period.

Roche Company Profile

Roche Holding AG engages in the pharmaceuticals and diagnostics businesses in Europe, North America, Latin America, Asia, Africa, Australia, and Oceania. The company offers pharmaceutical products in the therapeutic areas of anemia, blood and solid tumors, dermatology, hemophilia, inflammatory and autoimmune, neurological disorders, ophthalmology, respiratory disorders, and transplantation.